Please try another search
Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company’s products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Johan Drott | 57 | 2013 | CEO, President & Director |
Niklas Prager | 53 | - | Chairman of the Board |
Per Wollmer | - | - | Member of the Scientific Advisory Board |
Carl Persson | - | - | Member of the Scientific Advisory Board |
Olof Borgå | - | - | Member of the Scientific Advisory Board |
Kristina Drott | 52 | 2012 | Director |
Anna Torner | 59 | - | Director |
Peter Buhl Jensen | 68 | - | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review